Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure… Jan 11, 2022
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral… Jan 5, 2022
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second… Dec 16, 2021
Braxia Scientific Wants To Offer Ketamine Treatments In ‘Less Restrictive’ Environments. Will It Be Safe? Dec 1, 2021
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus Nov 24, 2021
Can EEG Changes Help Predict Long-Term Response To Ketamine Treatment For Depression? Entheon Study Will Find Out Nov 15, 2021
